Transdermal Gasotransmitter Sensor (TAGS™)

TAGS is designed as a non-invasive point-of-care diagnostic technique for detection of endothelial dysfunction in the high risk diabetic population. It is based on a state-of-the-art sensing technique to detect the presence of and measure the concentration of biomarker of endothelial dysfunction, hydrogen sulfide [14]. Inspired by the office-based [17] system, the miniature home-based technology is currently under development at Exhalix.

When attached to the skin, TAGS can discriminate the condition of high concentration (healthy microvascular blood perfusion, BOTTOM) from low concentration (abnormally low perfusion, TOP).